Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Richapeslayer_pounce Dec. 7 at 6:49 AM

$BCTX huge amountof insider ownership.Here is a list ,Mark is conpany director. Here are the top 10 holders ( Top 10 BCTX Insider / Major Holder List (Copy & Paste Ready) 1. Marc Lustig – 3,595,870 shares – 10.03% 2. Jamieson Bondarenko – 769,856 shares – 4.07% 3. William V. Williams – 552,738 shares – 3.00% 4. CVI Investments, Inc. – 2,608,695 shares – 7.28% (not management but a major holder) 5. Giuseppe Del Priore – 160,000 shares – <1% 6. Vaughn Embro-Pantalony – 114,524 shares – <1% 7. Gadi Levin – 118,110 shares – <1% 8. Jane A. Gross – 90,000 shares – <1% 9. Martin E. Schmieg – 105,574 shares – <1% 10. Rebecca Taub – 50,000 shares – <1%

1 · Reply

superguild Dec. 6 at 9:42 PM

$BCTX if a $ 2B buyout suddennly showed up on Monday AM how would management cash in.? Do any of them have shares? Options sitting around? If not then i wouldnt expect anything to happen that might benefit current shareholders

0 · Reply

Richapeslayer_pounce Dec. 5 at 9:29 PM

$BCTX Look where it came down to pefectly at the last high for the gap fill ,with results next week on the 10th its obvious what happens next.Text book chart.

0 · Reply

ZacksResearch Dec. 5 at 6:44 PM

$BCTX Gains 19.6% in a Month Investor optimism around pipeline progress grows. BCTX us dropping three posters with encouraging Phase 2 survival data, strong safety in Phase 3, and multiple biomarker readouts showing potential for identifying patients most likely to benefit — including NLR, DTH, and Th1-biased cytokines. Plus, the pivotal Phase 3 study is ongoing with an interim analysis expected in 1H2026. See the complete stock outlook here👉 https://www.zacks.com/stock/quote/BCTX?cid=sm-stocktwits-0-quote_overview-oc-23717&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_23717

0 · Reply

letsdodiz Dec. 5 at 6:36 PM

$BCTX will we see this over $15 next week?

1 · Reply

JJBurch Dec. 5 at 3:36 PM

$QCLS I’m as close to 100% certain this shoots above $10 here today as I can be Just so certain of it. $PMCB $2 possible —should’ve a major parabolic mover today $IXHL in adding the dip for partnership news next week $BCTX holding. Will triple soon. Holding fo it Try not to let the negative self loathing loser trolls get in the way of this party

0 · Reply

JJBurch Dec. 5 at 11:17 AM

$IXHL $PMCB $QCLS $BCTX I repeat…

0 · Reply

JJBurch Dec. 5 at 2:02 AM

$BCTX $IXHL $PMCB $QCLS It’s worth just looking at the success from just this one post. Look at that! Whew

0 · Reply

JJBurch Dec. 4 at 4:43 PM

$BCTX please note the new FDA may approve their drug NOW with Ph2 and all current data from ongoingPh3 $IXHL Bios are going to get so hot now https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

2 · Reply

JJBurch Dec. 4 at 2:22 PM

$QCLS $PMCB $IXHL $BCTX Now recent trolls have been unblocked Come at me bros. Hahahahaha

0 · Reply

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 11 days ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 16 days ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 18 days ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 4 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 4 weeks ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 22, 2025, 7:30 AM EDT - 6 weeks ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 21, 2025, 7:50 AM EDT - 6 weeks ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 6 weeks ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 6 weeks ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 7 weeks ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 2 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 3 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 3 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 3 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 4 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 4 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 4 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 4 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 4 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 5 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 5 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 5 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 5 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 5 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 5 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 5 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 6 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 6 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 7 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 7 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 7 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 7 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 8 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 10:11 AM EDT - 8 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 7:30 AM EDT - 8 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 23, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 22, 2025, 7:30 AM EDT - 8 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 16, 2025, 7:30 AM EDT - 8 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 9 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 20, 2025, 8:00 AM EDT - 9 months ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Feb 5, 2025, 6:15 PM EST - 10 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 4:05 PM EST - 10 months ago

BriaCell Therapeutics Announces Closing of Public Offering

Feb 3, 2025, 7:59 PM EST - 10 months ago

BriaCell Therapeutics Announces Pricing of Public Offering

Feb 3, 2025, 4:45 PM EST - 10 months ago

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

Feb 3, 2025, 7:30 AM EST - 10 months ago

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Richapeslayer_pounce Dec. 7 at 6:49 AM

1 · Reply

superguild Dec. 6 at 9:42 PM

0 · Reply

Richapeslayer_pounce Dec. 5 at 9:29 PM

$BCTX Look where it came down to pefectly at the last high for the gap fill ,with results next week on the 10th its obvious what happens next.Text book chart.

0 · Reply

ZacksResearch Dec. 5 at 6:44 PM

0 · Reply

letsdodiz Dec. 5 at 6:36 PM

$BCTX will we see this over $15 next week?

1 · Reply

JJBurch Dec. 5 at 3:36 PM

0 · Reply

JJBurch Dec. 5 at 11:17 AM

$IXHL $PMCB $QCLS $BCTX I repeat…

0 · Reply

JJBurch Dec. 5 at 2:02 AM

$BCTX $IXHL $PMCB $QCLS It’s worth just looking at the success from just this one post. Look at that! Whew

0 · Reply

JJBurch Dec. 4 at 4:43 PM

2 · Reply

JJBurch Dec. 4 at 2:22 PM

$QCLS $PMCB $IXHL $BCTX Now recent trolls have been unblocked Come at me bros. Hahahahaha

0 · Reply

JJBurch Dec. 4 at 2:19 PM

$QCLS $PMCB $IXHL $BCTX Just musing: I’m having THE best money making week of my life And knowing it’s just the start is nearly unbelievable. Congrats to all the Good People You know who you are I may unblock some trolls just so they can enjoy watching my success. I know how much they love that.

2 · Reply

JJBurch Dec. 4 at 1:46 PM

$BCTX $IXHL $PMCB $QCLS $XBI My ALL IN LIST

0 · Reply

JJBurch Dec. 4 at 1:29 PM

$PMCB This one may actually be the biggest winner of all, alongside $QCLS I’m buying so huge into both of these as I watch my MASSIVE investment in $IXHL quadruple over the next few weeks *with $BCTX on the side Watch these stocks Make money with me. And I mean MASSIVE MASSIVE money $XBI

1 · Reply

Richapeslayer_pounce Dec. 4 at 10:53 AM

$BCTX I see this going to at least $120 to $150 on the 10th the float is tiny and impact of the news will be huge.

2 · Reply

Richapeslayer_pounce Dec. 4 at 10:52 AM

$BCTX Times to buy are before results , times to sell 12 hours after results.If people are stupid enough to hold long term don't complain the company is terrible , thier job is to dillute to get the drug to market the comany has done well , you are a poor investor.The only other time to invest long is prior to break even after release of the product.

0 · Reply

GoldenChic Dec. 4 at 5:43 AM

$BCTX still need $250 pos to get even

1 · Reply

superguild Dec. 3 at 11:49 PM

$BCTX why wouldnt they want to get price up so warrants get exercised at 53$? Cause I dont think they want any of the warrants to ever be exercised . Management waiting and will structure their options to maxkmize their gain so dont want warrant dilution. Will likely R/S again to make them essentially worthless

2 · Reply

makedatbread88 Dec. 3 at 11:15 PM

$BCTX low floater setting up into catalyst on December 10th 1 week chart bullish keep an eye

0 · Reply

LeftyT Dec. 3 at 10:00 PM

$BCTX Something finally beginning to percolate here??? Could there be some new data leaking out from the SABCS presentation for next week? Let's go!!!

1 · Reply

Fvalstounge Dec. 3 at 6:50 PM

$BCTX One has to dig deep and watch carefully, to find clues. Previous publications detailed the cytokines and co-stimulatory molecules to be expressed in the Bria-OTS+ platform. Among them was 4-1BBL (to increase T-cell activation and survival). More recent publications not only omit this protein, but they have added CD40L to later cell lines (melanoma and NSCLC). I see two reasons for this. For one, 4-1BBL takes up a lot of vector space. One can only cram so many expressions into the "cargo" space. It also takes additional engineering to keep it on the cell and getting uniform expressions. Complicates GMP manufacturing. Thus, eliminating this expression creates room for other, less burdensome (but equally effective) expressions like CD40L. On the other hand, while 4-1BBL would boost the T-cells response mediated through class I HLA's, the CD40L would boost dendritic cell activity, and be primarily mediated through class II HLA's. Just lightening the load, or a shift in priorities?

0 · Reply

DunkenInvest Dec. 3 at 6:33 PM

$BCTX We're so back. 12,40$! Back in green total 🥳 Let's keep going 🕺💃

0 · Reply

Fvalstounge Dec. 3 at 5:40 PM

$BCTX Per the SABCS abstract: "Pts w/ vs w/o prior CDK4/6i , mPFS was 3.8 vs 2.1 (HR: 0.5; 95% CI 0.3 – 0.9, p = .03)" A hazard ratio of 0.5 for this subgroup is one of the strongest signals thus far. I wonder what is driving the response to those with prior CDK4/6 inhibitors. It's very notable, since most HR+ patients have this exposure in earlier lines of treatment.

1 · Reply

Market Cap	21.46M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	50,500
Avg Vol	68,618
Day's Range	N/A - N/A
Shares Out	1.88M
Stochastic %K	68%
Beta	1.38
Analysts	Strong Buy
Price Target	$40.00